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SUMMARY
A simple histological method to evaluate the Leydig cell compartment is lacking. We aimed to establish such a method and to
investigate if Leydig cell hyperplasia of the biopsy contralateral to the tumour-bearing testicle in patients with testicular germ cell
cancer is associated with biochemical signs of Leydig cell dysfunction after long-term follow-up. A case group of 50 long-term testic-
ular germ cell cancer survivors without human chorionic gonadotropin elevation, 10 testicular germ cell cancer patients with ele-
vated human chorionic gonadotropin and 10 controls without testicular malignancy were included. For each subject, 2–4
representative sections from their testicular biopsies were selected for analysis. Using the image processing program ImageJ (V.1.48,
NIH), an area with a minimum of 50 tubules was selected and delineated (total selected area) and the total Leydig cell area was calcu-
lated by adding up every delineated Leydig cell group within the total selected area. Four different methods were tested for the ability
to quantify the Leydig cell compartment. In the 50 testicular germ cell cancer survivors, associations between the area of the Leydig
cell compartment and serum levels of testosterone and luteinising hormone were investigated using linear regression analysis. The
Leydig cell compartment was best quantified by the total Leydig cell area/total selected area index, which was significantly larger in
the human chorionic gonadotropin-positive patients than in controls (P = 0.00001). In the 50 human chorionic gonadotropin-nega-
tive testicular germ cell cancer survivors, increasing total Leydig cell area/total selected area was significantly associated with
decreased levels of total testosterone and decreased total testosterone/luteinising hormone ratio after a median of 9-year follow-up.
In conclusion, a new simple method, total Leydig cell area/total selected area, was established to estimate the Leydig cell compart-
ment in testicular biopsies. The index identified Leydig cell hyperplasia in the contralateral biopsy in patients with testicular germ
cell cancer, and it was associated with long-term biochemical Leydig cell dysfunction. Although in testicular germ cell cancer sur-
vivors, the clinical value is limited because the contralateral biopsies are not commonly available, we propose a closer andrological
follow-up in any patient with an increased total Leydig cell area/total selected area index.
INTRODUCTION
An enlarged Leydig cell compartment, commonly described as
Leydig cell hyperplasia (LCH), is associated with poor testicular
function and has been found in infertile men, men with Klinefel-
ter syndrome and patients with testicular germ cell cancer
(TGCC) (Ahmad et al., 1969, 1971; Holm et al., 2003). In these
studies, the area of the Leydig cell compartment was quantified
using stereological or histological methods (Ahmad et al., 1971;
Holm et al., 2003). However, in clinical practice, stereological
evaluation is not feasible, and simple histological assessment
has been questioned as non-reproducible. Leydig cell function is
currently assessed in the clinical setting by measuring serum
levels of testosterone and luteinizing hormone (LH). A more
objective method to assess the Leydig cell compartment would
be a useful tool for clinicians in andrology centres, where testic-
ular biopsies are commonly performed to assess spermatogene-
sis or the presence of pre-invasive germ cell neoplasia in situ
(GCNIS).
Patients with TGCC are at risk of biochemical Leydig cell dys-
function manifested as increased serum levels of LH with or
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without corresponding low levels of testosterone and many of
them will undergo treatment that can further impair the func-
tion of the remaining testicle (Sprauten et al., 2014; Bandak
et al., 2016; Isaksson et al., 2017). We hypothesized that patients
with Leydig cell hyperplasia (LCH) at the time of diagnosis were
at increased risk of long-term Leydig cell dysfunction. We were
able to address this hypothesis as we have access to archived
biopsies from the testicle contralateral to the tumour-bearing
one, a procedure which is routinely performed in Denmark (and
electively in several other European centres) to screen for the
presence of GCNIS (Berthelsen et al., 1982; Kier et al., 2015), pre-
viously known as testicular carcinoma in situ (CIS) (Berney
et al., 2016). Furthermore, in a previous study, we have collected
detailed data on testicular function, including reproductive hor-
mone profiles, in a series of long-term TGCC survivors (Bandak
et al., 2017a).
Thus, there were two aims of the present study: Aim 1: to
establish a simple, reproducible method to quantify the Leydig
cell compartment in testicular biopsies in order to define LCH,
and Aim 2: to test the clinical value of this method by investigat-
ing if LCH identified by this method in biopsies from the con-
tralateral testicle in patients with TGCC is associated with
biochemical signs of Leydig cell dysfunction during long-term
follow-up.
MATERIALS ANDMETHODS
Study subjects
We included 50 patients with hCG-negative TGCC treated
from 1984 through 2012 at Copenhagen University Hospital,
Rigshospitalet. These patients were included among the 158
participants of the clinical study ‘Symptoms and Clinical Signs
of Hypogonadism in Testicular Cancer Survivors’ (ClinicalTri-
als.gov number, NCT02240966) which was conducted from 2014
through 2016. Inclusion and exclusion criteria for NCT02240966
are described elsewhere (Bandak et al., 2017a). For this study,
additional selection criteria were as follows: the availability of a
contralateral biopsy of good technical quality, absence of GCNIS
in the biopsy and normal hCG concentration in blood at the time
of diagnosis. The final number of the patients (50) was also influ-
enced by feasibility, because the histological evaluation, slide
scanning and manual delineation of Leydig cells required a long
time. The histological tumour type was recognized by experi-
enced pathologists as seminoma in 29 patients and non-semi-
noma in 21 patients (Table 1). The absence of GCNIS in the
biopsy was confirmed by immunohistochemical staining for at
least one GCNIS marker (Rajpert-De Meyts et al., 2015; Rajpert-
De Meyts & Grigor, 2017).
As a control group of men expected to have a normal Leydig
cell area, we included 10 men without testicular malignancy in
whom bilateral testicular biopsies had been performed as a part
of the clinical workup for infertility due to obstructive azoosper-
mia. These men had serum levels of testosterone and LH within
the normal range. There were not many of such biopsies avail-
able, because the diagnosis of obstructive azoospermia can be
established without an open biopsy. Only biopsies with normal
testicular histology with complete spermatogenesis could be
included, hence further limiting the size of the control group.
Finally, in order to investigate a group of men expected to have a
substantially enlarged Leydig cell compartment due to stimula-
tion by hCG (Asa et al., 1984; Mendis-Handagama, 1997; Lottrup
et al., 2014), we included 10 patients with TGCC whose serum
Table 1 Clinical characteristics and serum levels of hormones reflecting Leydig cell function in 50 long-term hCG-negative testicular germ cell cancer sur-
vivors with or without Leydig cell hyperplasia of the non-tumour-bearing testicle at the time of diagnosis
Patients WITHOUT Leydig cell hyperplasia (n = 28) Patients WITH Leydig cell hyperplasia (n = 22) P-value
Age at diagnosis* 31 (27–37) 32 (26–37) 0.9
Follow-up since biopsy 7 (4–13) 13 (5–17) 0.2
Age at follow-up 43 (36–48) 48 (40–51) 0.4
Histology
Seminoma 17 (61%) 12 (55% and 45%)
Non-seminoma 11 (60% and 40%) 10 (46%) 0.3
Treatment
Orchiectomy alone 10 (36%) 10 (45.5%)
Chemotherapy 13 (46%) 10 (45.5%)
Abdominal radiotherapy 5 (18%) 2 (9%) 0.3
Pre-orchiectomy markers of Leydig cell function (n = 17) (n = 12)
LH (IU/L) 2.5 (1.8–5.5) 5.0 (3.4–6.2) 0.1
LH (% of expected according to age) 77 (48–164) 152 (100–186) 0.1
Total testosterone (nmol/l) 16.3 (13.9–22.4) 12.9 (10.4–14.4) 0.05
TT (% of expected according to age) 95 (81–116) 74 (61–83) 0.04
Total testosterone/LH 4.8 (3.4–10.8) 2.7 (1.8–5.5) 0.3
Leydig cell function at follow-up
LH (IU/L) 5.7 (4.0–9.0) 8.9 (5.9–12.8) 0.1
LH (% of expected according to age) 165 (120–279) 258 (172–370) 0.1
Total testosterone (nmol/l) 12.9 (11.4–16.4) 11.8 (7.5–13.6) 0.06
TT (% of expected according to age) 87 (75–110) 77 (49–92) 0.08
Total testosterone/LH 2.3 (1.3–3.4) 1.2 (0.7–2.4) 0.02
Changes in Leydig cell function (n = 17) (n = 12)
LH (percentage point) 57 (2–92) 82 (29–122) 0.1
TT (percentage point) 3 (21–12) 2 (28–21) 0.7
Ultrasound characteristics at follow-up
Size of the testicle (ml) 19 (11–24) 10 (8–14) 0.002
Presence of microlithiasis 5 (18%) 5 (23%) 0.7
*Median, (interquartile range).
2 Andrology, 1–8 © 2018 American Society of Andrology and European Academy of Andrology
M. G. Tarsitano et al. ANDROLOGY
levels of hCG were highly elevated (designated in this study as
‘patients with hCG-positive TGCC’). Selection criteria of the
patients with hCG-positive TGCC were as follows: (1) a preoper-
ative serum level of hCG >1000 IU and (2) availability of a con-
tralateral biopsy of good size and technical quality. From 14
available biopsies fulfilling these selection criteria, we randomly
selected 10 biopsies to match the number of controls. The study
was approved by the Regional Ethical Committee (H-3-2013-
175).
Evaluation of the Leydig cell compartment in testicular
biopsies
For each testicular biopsy, we had 10 archived haematoxylin
and eosin (HE)-stained microscopy slides. In the two groups of
TGGC patients in whom a unilateral biopsy was taken from
the testicle contralateral to the tumour-bearing testis, we
selected every other slide, to have a minimum distance of 100
um between evaluated sections, thus avoiding overlapping Ley-
dig cell micronodules. This resulted in four slides pr. biopsy.
In the control group, bilateral biopsies were available; hence,
two slides from each of the two testicular biopsies (and four in
total) were analysed in the control group. A representative sec-
tion from 6 to 8 serial sections on each slide was selected for
analysis, and care was taken to avoid sections that were small
or mechanically traumatized. An area with a minimum of 50
cross sections of seminiferous tubules was selected for analy-
sis. The selected sections were scanned using a slide scanner,
NanoZoomer 2.0 HT (Hamamatsu Photonics, Herrsching am
Ammersee, Germany) and analysed using the software
NDPview version 1.2.36 (Hamamatsu Photonics). Using the
open-source image processing program ImageJ (V.1.48, NIH),
the total selected area (TSA) and the area of every single Leydig
cell group were manually delineated on the selected sections
(Fig. 1). The total Leydig cell area (TLCA) was calculated by
adding up the areas of all Leydig cell groups. To further
account for heterogeneity of a histological section due to the
presence of tubules with decreased spermatogenesis or Sertoli
cell-only pattern, which have smaller diameter than tubules
with complete spermatogenesis, the total number of tubules
(Ntub) in the four sections was calculated. Subsequently, the
following four methods were evaluated for the ability to quan-
tify the Leydig cell compartment and identify the samples with
obvious Leydig cell hyperplasia: (1) the mean Leydig cell area
of all delineated Leydig cell groups ‘mean Leydig cell area’ (2)
TLCA/TSA, (3) (TLCA/TSA)/Ntub and (4) TLCA/Ntub. The
index that best separated the patients with hCG-positive TGCC
from the controls was selected.
Two independent evaluations of a subset of the biopsies were
performed by MGT and ERDM to validate the methods. The two
investigators were blinded to the initial pathology reports’ evalu-
ation of the Leydig cell compartment (LC hyperplasia vs. no LC
hyperplasia) when they evaluated the biopsies.
Treatment and follow-up for the 50 patients with hCG-
negative TGCC
Stage I patients with TGCC (n = 20) were treated with unilat-
eral orchiectomy alone, while patients with disseminated dis-
ease (n = 30) were treated with unilateral orchiectomy and 3–4
courses of cisplatin-based chemotherapy; bleomycin, etoposide
and cisplatin (BEP) (n = 23), except for some patients with
seminoma stage II who were treated with unilateral orchiec-
tomy and abdominal radiotherapy (n = 7). The follow-up visit
was conducted at a median follow-up of 9 years (interquartile
range (IQR) 4–17 years) since diagnosis. At the follow-up visit,
blood samples were drawn for analysis of reproductive hor-
mones, systemic inflammation and metabolic profile (details
described in (Bandak et al., 2017a)). Testicular size and the
presence of microlithiasis were determined at the follow-up
visit using ultrasound equipment (Esaote myLab25 Gold, Gen-
ova, Italy).
Evaluation of reproductive hormones in the 50 patients with
hCG-negative TGCC
Leydig cell function was evaluated pre-orchiectomy and at
the follow-up visit, with blood samples drawn between 07.30
and 11.00 A.M. Serum concentration of LH was measured by
time-resolved immunofluorometric assay (Delfia; Perkin
Elmer, Turku, Finland) with intra-assay and interassay coeffi-
cients of variation (CV) below 5% and detection limits of
0.05 IU/l. Sex hormone-binding globulin (SHBG) and total
testosterone (TT) were measured with chemiluminescent
immunoassay (Access2; Beckman Coulter) with intra-assay
and interassay CVs below 5% and detection limit of
<0.35 nmol/l. At the time of TGCC diagnosis, total testos-
terone was measured by radioimmunoassay (Siemens Coat-a-
count, Cruinn Diagnostics Limited, Dublin, Ireland) with a
detection limit of <0.23 nmol/l and intra-assay and interassay
CVs on 17% and 12.8%, respectively. The hormone measure-
ments were performed at the certified hormone laboratory at
the Department of Growth & Reproduction, Rigshospitalet,
Copenhagen, Denmark.
Statistical evaluation of associations between Leydig cell
histology and function
Continuous outcomes are presented as median with
interquartile range (IQR), while categorical outcomes are pre-
sented as total number and percentages. The Leydig cell com-
partment as quantified by each of the four different methods
mentioned above was compared between the control group and
the hCG-positive TGCC patients with independent samples t-
test, and the method which separated the two groups with the
greatest accuracy was chosen for investigating aim 2.
Subsequently, in the 50 patients with hCG-negative TGCC, lin-
ear regression analysis was performed with (1) pre-orchiectomy
levels, (2) follow-up levels and (3) changes in LH and TT, and
TT/LH as dependent variable and Leydig cell area in the con-
tralateral biopsy according to the new method for quantification
of the Leydig cell compartment as independent variable. To
adjust for age, we calculated percentage of predicted values of
TT and LH by dividing each individual value with the mean
value of age-matched controls. The method of calculation per-
centage of predicted values and the controls have been
described in a previous publication (Bandak et al., 2017b).
We then compared LH, TT, TT/LH and other characteristics of
the 50 hCG-negative TGCC patients with and without LCH of
the contralateral testicle according to the new method for quan-
tification of the Leydig cell compartment using chi-squared test
or independent samples t-test.
Finally, to further validate our new method for quantification
of the Leydig cell compartment, we performed receiver
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operating characteristic (ROC) curve analysis testing the new
method against the evaluation of the Leydig cell compartment
(LCH vs. no LCH) performed at the time of diagnosis.
All statistical tests were computed in IBM SPSS Statistics, ver-
sion 22.0. Armonk, NY: IBM Corp, and a two-sided P-value <0.05
was considered statistically significant.
(A) (B)
(C) (D)
(E) (F)
(G) (H)
Figure 1 Examples of histology and Leydig cell area delineation in contralateral testicular biopsies in the studied TGCC groups and controls. The images on
the left (A, C, E, G) show overview of the section, and the images on the right (B, D, F, H) show a higher magnification of the sections, with Leydig cell areas
delineated in yellow using ImageJ software. (A, B) A control subject with obstructive azoospermia without testicular malignancy and normal testicular histol-
ogy, including normal Leydig cell distribution. (C, D) A TGCC patient with highly elevated human chorionic gonadotropin (hCG) and Leydig cell hyperpla-
sia. (E, F) An example of a contralateral biopsy from a patient with TGCC from the follow-up group without elevation of hCG and with a normal Leydig cell
distribution. (G, H) An example from a patient with TGCC from the follow-up group without elevation of hCG but with Leydig cell hyperplasia.
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RESULTS
Quantification of the Leydig cell compartment and definition
of Leydig cell hyperplasia (aim 1)
The ability of each of the four methods to quantify the Leydig
cell compartment is shown in Fig. 2. The Leydig cell area was
significantly larger in patients with hCG-positive TGCC than in
the control group using the two methods, TLCA/TSA
(P = 0.00001) and (TLCA/TSA)/Ntub (P = 0.001). On the con-
trary, the Leydig cell area was significantly smaller in patients
with hCG-positive TGCC than in the control group when using
TLCA/Ntub (P = 0.01), while there was no difference in the
mean Leydig cell area between the two groups. In addition, we
found that the total number of tubules in the evaluated areas
was significantly higher in the hCG-positive group and lower in
controls than in the patients with hCG-negative TGCC (Supple-
mentary Table 1).
As the index TLCA/TSA was able to completely separate the
controls and the hCG-positive patients with the lowest P-value
(Fig. 2), we decided to use this method to address aim 2. Using a
cut-off value for definition of LCH of TLCA/TSA > 9%, there was
no overlap between controls and the hCG-positive patients
which is shown with the horizontal line in Fig. 2.
To test our new definition of LCH against LCH as determined
by the evaluator at the time of diagnosis, we performed ROC
curve analysis for TLCA/TSA with LCH according to the initial
pathology report as golden standard. The area under the curve
was 0.85 (95% confidence interval 0.73–0.96) (P < 0.001). When
using LCH according to the initial pathology report as golden
standard, we found a sensitivity of 84% and specificity of 81% of
the new definition of LCH (TLCA/TSA > 9%). When using the
new definition of LCH as golden standard, we found a sensitivity
of 73% and a specificity of 93% of LCH according to the initial
pathology report.
Association between Leydig cell hyperplasia and biochemical
Leydig cell dysfunction in patients with TGCC (aim 2)
Using the new definition of LCH (TLCA/TSA > 9%), 22 of the
50 patients with hCG-negative TGCC had LCH identified in the
biopsy of the contralateral testicle at the time of diagnosis
(Table 1). Patients with LCH had significantly lower TT
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(percentage of predicted according to age) at the time of diagno-
sis, and a significantly lower TT/LH ratio at follow-up. Further-
more, testicular size at follow-up was significantly smaller in TC
patients with LCH.
Increasing degree of the TLCA/TS index in the contralateral
biopsy was significantly associated with biochemical signs of
Leydig cell dysfunction at follow-up with decreased TT (percent-
age of expected according to age) as well as decreased TT/LH
(Fig. 3). The trend appeared to be the same independently of
treatment modality. There were no significant associations
between increasing Leydig cell area and biochemical Leydig cell
dysfunction at the time of diagnosis, as well as increasing Leydig
cell area and changes in Leydig cell function between diagnosis
and follow-up (Figure S2–S3).
DISCUSSION
In this study, we attempted to establish a semiquantitative
and clinically applicable method to estimate the Leydig cell area
in testicular biopsies, as the histological description of the Ley-
dig cell compartment is currently based on the subjective
impression of the evaluator. We found that it is possible to quan-
tify the Leydig cell compartment by manual delineation using
the publicly available image processing program ImageJ. Using
the index (TLCA/TSA), which reflects the fraction of the total
area of a biopsy section occupied by Leydig cells, we were able
to separate controls with a normal Leydig cell compartment and
a group of TGCC patients with highly elevated serum hCG levels
who had an enlarged Leydig cell area.
Secondly, in patients with hCG-negative TGCC, we found that
increased area of the Leydig cell compartment and LCH of the
testicle without malignancy was associated with long-term bio-
chemical signs of Leydig cell dysfunction, reflected by decreased
serum levels of total testosterone and decreased total testos-
terone/LH ratio. Although the androgen status is easily evaluated
by simply measuring hormone levels in blood, this finding could
be of importance for clinicians in cases when testicular biopsy
has been performed. The presence of LHC in patients with TGCC
at the time of diagnosis might alert clinicians to perform closer
follow-up for early detection of biochemical signs and symptoms
of Leydig cell dysfunction. We are currently investigating if TC
survivors with biochemical Leydig cell dysfunction without obvi-
ous symptoms would benefit from testosterone substitution
(Bandak et al., 2017b).
There were previous attempts to quantify the Leydig cell com-
partment in testicular biopsies. In a cross-sectional study of 95
patients, including 66 patients with infertility, Holm et al. inves-
tigated the Leydig cell compartment using semistereological
methods and examined possible associations with serum levels
of reproductive hormones (Holm et al., 2003). In 66 infertile
men, they found a significant correlation between the presence
of Leydig cell micronodules defined as clusters with more than
15 Leydig cells and increasing serum levels of LH and decreased
TT/LH. Our results using a simple semiquantitative method to
determine the Leydig cell area are in line with these findings and
further support the association between LCH and biochemical
Leydig cell dysfunction.
0
100
200
300
400
500
600
700
0 5 10 15 20 25
LH
  %
 o
f e
xp
ec
te
d
(Total Leydig cell area/Total selected area) * 102
LH, percent of expected
β =  4.5 (–1.0–10.0) p = 0.1 
0
2
4
6
8
10
12
0 5 10 15 20 25
TT
/L
H
(Total Leydig cell area)/Total selected area * 102
Total testosterone/LH 
β = –0.1 (–0.2;–0.02) p = 0.01
0
20
40
60
80
100
120
140
160
0 5 10 15 20 25
To
ta
l t
es
to
st
er
on
e 
%
 o
f e
xp
ec
te
d 
(Total Leydig cell area/Total selected area) * 102
Total testosterone, percentage of expected 
β = –2.0 (–3.0;–0.6)  p = 0.005
Orchiectomy 
alone
BEP
Radiotherapy
Figure 3 Results of a linear regression analysis with Leydig cell area of the
non-tumour-bearing contralateral testicle (Total Leydig cell area/total
selected area) as independent variable and serum total testosterone (per-
centage of expected according to age) serum LH (percentage of expected
according to age) and total testosterone/LH at follow-up as dependent vari-
able in 50 long-term testicular germ cell cancer survivors. (● represents
patients treated with orchiectomy alone,▲, represents patients treated with
radiotherapy, and ■ represents patients treated with bleomycin, etoposide
and cisplatin).
6 Andrology, 1–8 © 2018 American Society of Andrology and European Academy of Andrology
M. G. Tarsitano et al. ANDROLOGY
Adding a semiquantitative evaluation of the Leydig cell com-
partment would require some extra time for the pathologist/an-
drologist that provides a report on the testicular biopsy. Based
on our experience, we estimate that manual delineation and cal-
culating of the areas would take approximately 30 min per
patient, which could possibly decrease to 15 min in experienced
hands. Future development of the method could include
immunohistochemical staining for a Leydig cell marker, for
example steroidogenic enzyme 3-beta-hydroxysteroid dehydro-
genase (3BHCD), followed by an automatic calculation of the
area of stained cells by image software, which would eliminate
the need for manual delineation of the Leydig cell groups. How-
ever, regardless of the LCA calculation method, this test ought to
be performed primarily in andrology centres and in certain cases
where the evaluation of Leydig cell function is essential, for
example in patients suspected of testosterone deficiency and in
patients with TGCC, in whom a contralateral biopsy is available.
Several factors such as small testicular size and presence of
microlithiasis (Eberhard et al., 2008; P€uhse et al., 2011), biochemi-
cal Leydig cell dysfunction at the time of diagnosis (Bandak et al.,
2017c; Eberhard et al., 2008) and chemotherapy and radiotherapy
have been associated with long-term risk of Leydig cell dysfunction
and manifest testosterone deficiency in patients with TGCC (Ban-
dak et al., 2016). In the present study, ultrasonic size of testicle
without a tumour evaluated at the follow-up was significantly
smaller in patients with LCH, while there was no difference in the
prevalence of microlithiasis among patients with or without LCH.
A correlation between small testicular size and Leydig cell hyper-
plasia has been reported in other studies (Ahmad et al., 1971; Holm
et al., 2003). However, in the present study, ultrasonic evaluation
was performed many years after the testicular biopsy was per-
formed, and the initial data were available only in a handful of
patients, so it cannot be excluded that testicular size at follow-up is
not comparable to ultrasonic size at the time when the biopsy was
taken. The association between LCH and biochemical Leydig cell
dysfunction appeared to be the same across treatment groups
(orchiectomy alone, BEP, RT), although the sample size was too
small to test this in a statistically meaningful manner. As measuring
of serum levels of LH and TT and ultrasonic evaluation of the testi-
cle are easily performed, it remains to be seen if LCH according to
our proposed method adds additional prognostic value for estimat-
ing the risk of long-term Leydig cell dysfunction. However, to
answer this question, a prospective study is needed, including sys-
tematic ultrasonic evaluation combined with hormone profiles and
a registration of early signs of androgen insufficiency.
The main strength of the present study is a detailed andrologi-
cal characterization of the patients with TGCC, including testis
size and reproductive hormones, as well as an access to a unique
material of the contralateral biopsy. This study confirms the
value of this procedure, which gives an insight not only into the
presence of GCNIS, but also into the function of the remaining
testicle at the time of orchiectomy, including Leydig cell func-
tion and quality of spermatogenesis, although screening for
GCNIS remains the main indication (Rajpert-De Meyts & Grigor,
2017). However, the LHC is a warning sign, while the presence of
at least some tubules with late spermatids is a positive finding,
especially for the patients in whom semen cryopreservation
could not be performed before orchiectomy.
The limitations of this study include a retrospective set-up, the
modest sample size and the heterogeneity of treatment
modalities among patients with hCG-negative TGCC. As only
approximately half of the patients had Leydig cell function eval-
uated before orchiectomy, the study is possibly underpowered
to evaluate these associations as well as changes in Leydig cell
function. In addition the different methods used for analysis of
serum levels of testosterone at diagnosis and at follow-up are a
limitation. However, as we calculated percentage of predicted
value based on reference values from age-matched controls
analysed with the same methods, we have tried to adjust for the
change in method. Another problem is the histological hetero-
geneity and different quality of spermatogenesis, which can
affect the calculations of the TLCA/TSA index. By choosing four
representative slides with a minimum of 50 tubules and count-
ing the number of tubules within TSA, we attempted to account
for tissue heterogeneity and different diameters of the tubules.
We found a higher total number of tubules in the evaluated
slides of hCG-positive patients, suggesting increased tissue
heterogeneity or impaired spermatogenesis in this group of
patients. We tried to adjust for these differences by dividing
TLCA/TSA with the total number of tubules and by evaluation
the index TLCA/Ntub; however, these adjustments did not
improve the ability to separate the patients with hCG-positive
TGCC from the control group. Future studies should further
investigate methods to account for diameter of tubules when
estimating the Leydig cell compartment. Finally, our test is of
limited clinical value for patients with TGCC, because systematic
screening for contralateral GCNIS in patients with TGCC is not
routine in most countries. Clinical guidelines suggest a con-
tralateral biopsy in patients <40 years of age with testicular vol-
ume <12 ml, history of cryptorchidism or poor spermatogenesis
(Albers et al., 2011). These patients already carry an increased
risk of poor Leydig cell function and primary hypogonadism;
hence, it remains to be seen if presence of LCH of the contralat-
eral testicle has additional prognostic value in predicting
patients at high risk of developing symptoms of testosterone
deficiency.
CONCLUSION
A new semiquantitative method allowing a quick and objective
evaluation of the Leydig cell compartment in a testicular biopsy
was found and assessed for clinical application. The index, based
on a calculation of the fraction of the total area of a biopsy occu-
pied by Leydig cells, was able to accurately distinguish patients
with Leydig cell hyperplasia from those with a normal Leydig cell
compartment. In patients with testicular germ cell cancer, the
presence of an enlarged Leydig cell compartment in the biopsy
contralateral to the tumour-bearing testicle was associated with
biochemical Leydig cell dysfunction during the long-term fol-
low-up period. Closer andrological follow-up of these patients
might be suggested. Further prospective studies should validate
this method, and future perspectives include automatic delin-
eation of the Leydig cell area.
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SUPPORTING INFORMATION
Additional supporting information may be found online in the Support-
ing Information section at the end of the article:
Figure S1 Scatter plots showing the number of tubules in the evaluated
slides. Each p-value represents comparison between the 10 controls with
obstructive azoospermia and the 10 hCG-positive testicular germ cell
cancer patients.
Figure S2 Results of a linear regression analysis with Leydig cell area of
the non-tumour bearing testicle (Total Leydig cell area/total selected area)
as independent variable and serum total testosterone (percent of
expected according to age where 100% corresponds to the mean value of
an age-matched man) serum LH (percent of expected according to age)
and total testosterone/LH at the time of diagnosis as dependent variable
in 29 long-term testicular germ cell cancer survivors with available repro-
ductive hormones.
Figure S3 Results of a linear regression analysis with Leydig cell area of
the non-tumour bearing testicle (Total Leydig cell area/total selected area)
as independent variable and changes in serum total testosterone (percent
of expected according to age) and serum LH (percent of expected accord-
ing to age where 100% corresponds to the mean value of an age-matched
man) as dependent variable in 29 long-term testicular germ cell cancer
survivors with available reproductive hormones. (● represents patients
treated with orchiectomy alone, ▲, represents patients treated with
radiotherapy and ■ represents patients treated with bleomycin, etopo-
side and cisplatin).
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